Home | All trials

[RDF data]
Trial NCT00000336

Resource URI: http://static.linkedct.org/resource/trials/NCT00000336
PropertyValue
linkedct:brief_title Selegiline in Outpatient Treatment for Cocaine Dependence - 1
linkedct:condition <http://static.linkedct.org/resource/condition/2992>
linkedct:criteria Inclusion Criteria: M/F ages 21-50. Meets DSM-IV critera for cocaine. Agreeable to conditions of study and signed informed consent. Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 50 Years
linkedct:eligibility_minimum_age 21 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date September 20, 1999
linkedct:id NCT00000336
rdfs:label Trial NCT00000336
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute on Drug Abuse (NIDA)
linkedct:location <http://static.linkedct.org/resource/location/209856>
linkedct:nct_id NCT00000336
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title Safety and Efficacy of Selegiline in Outpatient Treatment for Cocaine
linkedct:org_study_id NIDA-3-0010-1
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/60742>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000336>
linkedct:phase Phase 2
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/20169>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/25660>
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/8469>
linkedct:secondary_id Y01-3-0010-1
linkedct:source National Institute on Drug Abuse (NIDA)
linkedct:start_date January 1995
linkedct:study_design Treatment, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary The purpose of this study is to evaluate the efficacy and clinical safety of selegiline in the treatment of cocaine dependence and to assess neurotoxicity (Magnetic Resonance Imaging, MRI) post-hoc as a possible variable for future stratification in clinical trials.
rdf:type linkedct:trials
linkedct:verification_date January 1996